Vorapaxar, a novel oral antiplatelet drug.
Loading...
Date
2015-01
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Vorapaxor is first in the class of protease activated receptor 1 (PAR 1) antagonists.
It acts by inhibiting the binding of thrombin to PAR 1 and thereby prevents platelet
aggregation. USFDA approved it in May 2014 as the results of clinical trials showed
that the benefit: risk ratio was high. It is to be used in a dose of 2.5 mg once daily as
triple antiplatelet therapy with aspirin and clopidogrel for reduction of thrombotic
cardiovascular events in patients with a history of myocardial infarction or peripheral
arterial disease. Increase in the incidence of intracranial hemorrhage is the major
side-effect seen.
Description
Keywords
Vorapaxar, Protease activated receptor 1 antagonsit, Thrombin receptor antagonist
Citation
Tekulapally Kranti. Vorapaxar, a novel oral antiplatelet drug. International Journal of Basic & Clinical Pharmacology. 2015 Jan-Feb; 4(1): 188-190.